Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.
2.

Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation.

Ross JS, Hill KP, Egilman DS, Krumholz HM.

JAMA. 2008 Apr 16;299(15):1800-12. doi: 10.1001/jama.299.15.1800.

PMID:
18413874
3.

The ADVANTAGE seeding trial: a review of internal documents.

Hill KP, Ross JS, Egilman DS, Krumholz HM.

Ann Intern Med. 2008 Aug 19;149(4):251-8. Review.

PMID:
18711155
4.

Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance.

Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM.

Arch Intern Med. 2009 Nov 23;169(21):1976-85. doi: 10.1001/archinternmed.2009.394.

5.

Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies.

Madigan D, Sigelman DW, Mayer JW, Furberg CD, Avorn J.

Am Heart J. 2012 Aug;164(2):186-93. doi: 10.1016/j.ahj.2012.05.002. Epub 2012 Jul 3.

PMID:
22877803
6.

Drug safety: are we making progress?: comment on "pooled analysis of rofecoxib placebo-controlled clinical trial data".

Luepker RV.

Arch Intern Med. 2010 Jan 25;170(2):202. doi: 10.1001/archinternmed.2009.496. No abstract available.

PMID:
20101016
7.

Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation.

Graham DY, Jewell NP, Chan FK.

Am J Med Sci. 2011 Nov;342(5):356-64. doi: 10.1097/MAJ.0b013e3182113658.

8.

Rofecoxib for rheumatoid arthritis.

Garner SE, Fidan DD, Frankish RR, Judd MG, Towheed TE, Wells G, Tugwell P.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003685. Review.

PMID:
15674912
9.

Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial.

Aisen PS, Thal LJ, Ferris SH, Assaid C, Nessly ML, Giuliani MJ, Lines CR, Norman BA, Potter WZ.

Curr Alzheimer Res. 2008 Feb;5(1):73-82.

PMID:
18288935
10.

94% of patients suing Merck over rofecoxib agree to company's offer.

Charatan F.

BMJ. 2008 Mar 15;336(7644):580-1. doi: 10.1136/bmj.39513.541296.DB. No abstract available.

11.

American Society of Clinical Oncology policy statement: oversight of clinical research.

American Society of Clinical Oncology..

J Clin Oncol. 2003 Jun 15;21(12):2377-86. Epub 2003 Apr 29.

PMID:
12721281
12.

Rofecoxib in mild cognitive impairment.

Ownby RL.

Curr Psychiatry Rep. 2006 Feb;8(1):9-10. No abstract available.

PMID:
16513035
13.

Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.

Motsko SP, Rascati KL, Busti AJ, Wilson JP, Barner JC, Lawson KA, Worchel J.

Drug Saf. 2006;29(7):621-32.

PMID:
16808554
14.

Long-term risk of ischemic stroke associated with rofecoxib.

Afilalo J, Coussa-Charley MJ, Eisenberg MJ.

Cardiovasc Drugs Ther. 2007 Apr;21(2):117-20. Epub 2007 Mar 28.

PMID:
17393291
15.

Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.

Weir MR, Sperling RS, Reicin A, Gertz BJ.

Am Heart J. 2003 Oct;146(4):591-604. Review.

PMID:
14564311
16.

Failing the public health--rofecoxib, Merck, and the FDA.

Topol EJ.

N Engl J Med. 2004 Oct 21;351(17):1707-9. Epub 2004 Oct 6. No abstract available.

18.

Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial.

Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton DG, Riddell R, Iverson ER, Demets DL.

Lancet. 2008 Nov 15;372(9651):1756-64. doi: 10.1016/S0140-6736(08)61490-7. Epub 2008 Oct 14. Erratum in: Lancet. 2008 Nov 15;372(9651):1732.

PMID:
18922570
19.

Institutional review boards must conduct safety review.

Maloney DM.

Hum Res Rep. 2005 Feb;20(2):3. No abstract available.

PMID:
15839005
20.

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.

Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ.

Circulation. 2001 Nov 6;104(19):2280-8.

Supplemental Content

Support Center